Hospital Universitario de la Princesa -ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2022

  1. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  2. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  3. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002

2018

  1. Bmi1-progenitor cell ablation impairs the angiogenic response to myocardial infarction

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 9, pp. 2160-2173

2017

  1. Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 12, pp. 1430-1439

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

    Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327

2013

  1. Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype

    Genes Chromosomes and Cancer, Vol. 52, Núm. 8, pp. 753-763

2012

  1. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

  2. Transforming and tumorigenic activity of JAK2 by fusion to BCR: Molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase

    PLoS ONE, Vol. 7, Núm. 2

2011

  1. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

2008

  1. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

    Haematologica, Vol. 93, Núm. 7, pp. 1001-1008

2003

  1. De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19

    Genes Chromosomes and Cancer, Vol. 36, Núm. 4, pp. 406-412

1994

  1. Molecular analysis of chromosomh 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors

    International Journal of Cancer, Vol. 57, Núm. 2, pp. 172-175